← Leaderboards
Shannon Celeste Kenney
University Of North Carolina Chapel Hill
$30,359,662
Attributed
$32,930,757
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,930,757 · 18
By mechanism
R01$22,562,240 · 9
P01$7,763,038 · 5
U01$1,353,918 · 1
P30$916,933 · 2
R21$334,628 · 1
Top collaborators
- Eric C Johannsen5 shared
- Paul M. Lieberman3 shared
- Joseph M Salvino3 shared
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralCellsTumorHuman Herpesvirus 4B-LymphocytesVirusLymphomaProteinsEpstein-Barr Virus InfectionsLyticIn VitroMalignant NeoplasmsMouse ModelNeoplastic CellGenesPharmaceutical PreparationsViral ProteinsIn VivoGrowthPhenotypeAffectPathway InteractionsAcquired Immunodeficiency SyndromeMutant
Grant awards (99)
Roles of LMP1 and MYC in EBV-induced B-cell tumors$451,345
U01 · FY2025 · CA · contact PI
Project 3 - Latent and Lytic EBV Infection in Epithelial Cells$422,828
P01 · FY2025 · CA · contact PI
Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas$415,648
R01 · FY2025 · CA · contact PI
Human Cancer Virology$123,294
P30 · FY2025 · CA · contact PI
Roles of LMP1 and MYC in EBV-induced B-cell tumors$451,345
U01 · FY2024 · CA · contact PI
Project 3 - Latent and Lytic EBV Infection in Epithelial Cells$422,828
P01 · FY2024 · CA · contact PI
Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas$406,157
R01 · FY2024 · CA · contact PI
Human Cancer Virology$123,294
P30 · FY2024 · CA · contact PI
Effects of EBV Type on Viral Reactivation$521,858
R01 · FY2023 · AI · contact PI
Role of EBV Lytic Infection in Viral Tumorigenesis$498,279
R01 · FY2023 · CA · contact PI
Roles of LMP1 and MYC in EBV-induced B-cell tumors$451,228
U01 · FY2023 · CA · contact PI
Stringent Latent Epstein-Barr Virus (EBV) Infection Collaborates with Cellular Gene Alterations to Induce EBV+ Lymphomas$425,960
R01 · FY2023 · CA · contact PI
Human Cancer Virology$123,294
P30 · FY2023 · CA · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$72,407
P01 · FY2023 · CA · contact PI
Effects of EBV Type on Viral Reactivation$521,858
R01 · FY2022 · AI · contact PI
Role of EBV Lytic Infection in Viral Tumorigenesis$498,279
R01 · FY2022 · CA · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$403,005
P01 · FY2022 · CA · contact PI
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice$373,877
R01 · FY2022 · CA · contact PI
Human Cancer Virology Research Program$91,383
P30 · FY2022 · CA · contact PI
Effects of EBV Type on Viral Reactivation$521,858
R01 · FY2021 · AI · contact PI
Role of EBV Lytic Infection in Viral Tumorigenesis$508,447
R01 · FY2021 · CA · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$389,908
P01 · FY2021 · CA · contact PI
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice$381,507
R01 · FY2021 · CA · contact PI
Human Cancer Virology Research Program$109,840
P30 · FY2021 · CA · contact PI
Effects of EBV Type on Viral Reactivation$520,460
R01 · FY2020 · AI · contact PI
Role of EBV Lytic Infection in Viral Tumorigenesis$507,483
R01 · FY2020 · CA · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$393,288
P01 · FY2020 · CA · contact PI
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice$381,507
R01 · FY2020 · CA · contact PI
Human Cancer Virology Research Program$109,916
P30 · FY2020 · CA · contact PI
Role of EBV Lytic Infection in Viral Tumorigenesis$521,232
R01 · FY2019 · CA · contact PI
Effects of EBV Type on Viral Reactivation$519,621
R01 · FY2019 · AI · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$384,766
P01 · FY2019 · CA · contact PI
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice$370,061
R01 · FY2019 · CA · contact PI
Human Cancer Virology Research Program$109,920
P30 · FY2019 · CA · contact PI
Project 5 - EBV Drivers of Oncogenesis and Novel Therapies$393,288
P01 · FY2018 · CA · contact PI
EBV LMP1/LMP2A Proteins Promote Hodgkin-like Lymphomas in Humanized Mice$381,507
R01 · FY2018 · CA · contact PI
Human Cancer Virology Research Program$105,181
P30 · FY2018 · CA · contact PI
Human Cancer Virology Research Program$10,869
P30 · FY2018 · CA · contact PI
Human Cancer Virology Research Program$5,923
P30 · FY2018 · CA · contact PI
Human Cancer Virology Research Program$3,291
P30 · FY2018 · CA · contact PI
Human Cancer Virology Research Program$728
P30 · FY2018 · CA · contact PI
Epigenetic determinants of Epstein-Barr virus and cellular DNA in oral diseases$578,875
R01 · FY2017 · DE
Development of a Novel Inducer for EBV Lytic Therapy$546,954
R01 · FY2017 · CA
New Models and Treatments for AIDS-related Lymphoma$416,873
R01 · FY2017 · CA · contact PI
miRNA and v-Cdks: Independent Drivers OF EBV and HCMV Replication and Oncogenesi$392,337
P01 · FY2017 · CA · contact PI
Epigenetic determinants of Epstein-Barr virus and cellular DNA in oral diseases$578,875
R01 · FY2016 · DE
Development of a Novel Inducer for EBV Lytic Therapy$546,954
R01 · FY2016 · CA
New Models and Treatments for AIDS-related Lymphoma$416,873
R01 · FY2016 · CA · contact PI
miRNA and v-Cdks: Independent Drivers OF EBV and HCMV Replication and Oncogenesi$392,338
P01 · FY2016 · CA · contact PI
Development of a Novel Inducer for EBV Lytic Therapy$591,954
R01 · FY2015 · CA
Epigenetic determinants of Epstein-Barr virus and cellular DNA in oral diseases$578,875
R01 · FY2015 · DE
New Models and Treatments for AIDS-related Lymphoma$416,873
R01 · FY2015 · CA · contact PI
miRNA and v-Cdks: Independent Drivers OF EBV and HCMV Replication and Oncogenesi$395,189
P01 · FY2015 · CA · contact PI
Epigenetic determinants of Epstein-Barr virus and cellular DNA in oral diseases$578,875
R01 · FY2014 · DE
New Models and Treatments for AIDS-related Lymphoma$404,367
R01 · FY2014 · CA · contact PI
miRNA and v-Cdks: Independent Drivers OF EBV and HCMV Replication and Oncogenesi$383,420
P01 · FY2014 · CA · contact PI
Epigenetic determinants of Epstein-Barr virus and cellular DNA in oral diseases$578,875
R01 · FY2013 · DE
New Models and Treatments for AIDS-related Lymphoma$416,873
R01 · FY2013 · CA · contact PI
miRNA and v-Cdks: Independent Drivers OF EBV and HCMV Replication and Oncogenesi$392,338
P01 · FY2013 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$267,781
R01 · FY2013 · CA · contact PI
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells$357,875
P01 · FY2012 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$284,873
R01 · FY2012 · CA · contact PI
EBV-based Strategies for AIDS-related Malignancies$261,708
R01 · FY2012 · CA · contact PI
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells$358,724
P01 · FY2011 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$284,873
R01 · FY2011 · CA · contact PI
EBV-based Strategies for AIDS-related Malignancies$261,710
R01 · FY2011 · CA · contact PI
EBV-based Strategies for AIDS-related Malignancies$386,535
R01 · FY2010 · CA · contact PI
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells$370,720
P01 · FY2010 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$293,684
R01 · FY2010 · CA · contact PI
EBV-based Strategies for AIDS-related Malignancies$391,101
R01 · FY2009 · CA · contact PI
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells$364,363
P01 · FY2009 · CA · contact PI
EFFECT OF LYTIC EBV REPLICATION PROTEINS ON THE VIRUS AND HOST CELL$294,908
P01 · FY2009 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$293,684
R01 · FY2009 · CA · contact PI
EFFECT OF LYTIC EBV REPLICATION PROTEINS ON THE VIRUS AND HOST CELL$286,948
P01 · FY2008 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$278,599
R01 · FY2008 · CA · contact PI
EBV-based Strategies for AIDS-related Malignancies$276,467
R01 · FY2008 · CA · contact PI
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells$233,184
P01 · FY2008 · CA · contact PI
EBV Pathogenesis in a New Mouse Model$146,735
R21 · FY2008 · CA · contact PI
EFFECT OF LYTIC EBV REPLICATION PROTEINS ON THE VIRUS AND HOST CELL$284,068
P01 · FY2007 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$278,599
R01 · FY2007 · CA · contact PI
EBV-Based Strategies for AIDS-Related Malignancies$258,388
R01 · FY2007 · CA · contact PI
EBV Pathogenesis in a New Mouse Model$187,893
R21 · FY2007 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$287,499
R01 · FY2006 · CA · contact PI
EBV-Based Strategies for AIDS-Related Malignancies$265,870
R01 · FY2006 · CA · contact PI
EFFECT OF LYTIC EBV REPLICATION PROTEINS ON THE VIRUS$189,920
P01 · FY2006 · CA · contact PI
Regulation of EBV Infection in Epithelial Cells$294,419
R01 · FY2005 · CA
EBV-Based Strategies for AIDS-Related Malignancies$272,268
R01 · FY2005 · CA
EFFECT OF LYTIC EBV REPLICATION PROTEINS ON THE VIRUS$184,388
P01 · FY2005 · CA
Regulation of EBV Infection in Epithelial Cells$294,419
R01 · FY2004 · CA
EBV-Based Strategies for AIDS-Related Malignancies$272,268
R01 · FY2004 · CA
REGULATION OF EBV INFECTION IN EPITHELIAL CELLS$280,774
R01 · FY2003 · CA
EBV-Based Strategies for AIDS-Related Malignancies$272,268
R01 · FY2003 · CA
Cytotoxic Therapy/Induce/Lytic EBV/EBV-Malignancy$99,065
R01 · FY2003 · CA
REGULATION OF EBV INFECTION IN EPITHELIAL CELLS$274,549
R01 · FY2002 · CA
EBV BASED STRATEGIES FOR AIDS RELATED MALIGNANCIES$229,200
R01 · FY2002 · CA
REGULATION OF EBV INFECTION IN EPITHELIAL CELLS$268,506
R01 · FY2001 · CA
EBV BASED STRATEGIES FOR AIDS RELATED MALIGNANCIES$223,950
R01 · FY2001 · CA
REGULATION OF EBV INFECTION IN EPITHELIAL CELLS$262,636
R01 · FY2000 · CA
EBV BASED STRATEGIES FOR AIDS RELATED MALIGNANCIES$218,852
R01 · FY2000 · CA